- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Leukemia Research and Treatment
Volume 2013 (2013), Article ID 756703, 5 pages
New Quantitative Method to Identify NPM1 Mutations in Acute Myeloid Leukaemia
1Laboratoire d’Hématologie, Centre Hospitalier Lyon Sud, 165 chemin du Grand Revoyet, 69 495 Pierre-Bénite, France
2UMR 5239 CNRS, Faculté de Médecine Lyon Sud, 165 chemin du Petit Revoyet-BP 12, 69921 Oullins Cedex, France
3Service d’Hématologie 1G, Centre Hospitalier Lyon Sud, 165 chemin du Grand Revoyet, 69 495 Pierre-Bénite, France
Received 21 January 2013; Accepted 18 March 2013
Academic Editor: Massimo Breccia
Copyright © 2013 Sarah Huet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Somatic mutations in the NPM1 gene, which encodes for nucleophosmin, have been reported to be the most frequent genetic abnormalities found in acute myeloid leukaemia (AML). Their identification and quantification remain crucial for the patients’ residual disease monitoring. We investigated a new method that could represent a novel reliable alternative to sequencing for its identification. This method was based on high-resolution melting analysis in order to detect mutated patients and on an allele-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) for the identification and quantification of the transcripts carrying NPM1 mutations (NPM1m). Few patients carrying known NPM1m enabled us to set up a table with the different primers’ ΔCT values, identifying a profile for each mutation type. We then analysed a series of 337 AML patients' samples for NPM1 mutational status characterization and confirmed the ASO-RQ-PCR results by direct sequencing. We identified some mutations in 86 samples, and the results were fully correlated in 100% of the 36 sequenced samples. We also detected other rare NPM1m in two samples, that we confirmed by direct sequencing. This highly specific method provides a novel quick, useful, and costless tool, easy to use in routine practice.
Nucleophosmin mutations (NPM1m) occur in about one-third of acute myeloid leukaemias (AMLs) , and the current classification of myeloid neoplasms defined a recent entity of NPM1-mutated AML with distinct biological, clinical, and prognostic features . Moreover, the detection and quantification of NPM1m represents a major specific marker for the molecular monitoring of minimal residual disease (MRD) in AML, since it appears as an early initiating event in leukaemogenesis [3, 4]. The expression of this marker is very stable during disease evolution, and the detection of increasing NPM1m expression levels seems strongly predictive for impending haematological relapse [5, 6]. Finally, patients’ stratification in international clinical protocols and the development of new targeted therapies rely on the NPM1 status in AML . Thus, the identification of NPM1m is of critical importance for the AML patients’ admission process. Most of the NPM1m identified to date, as the type A mutation (75–80% of cases), are exon 12 frameshift mutations [1, 5, 8] leading to an aberrant accumulation of the protein in the cytoplasm . Several protocols and methods have been developed for the detection of NPM1m including DNA sequencing of different mutation-specific RT-PCR assays [10–13], denaturing high-performance liquid chromatography , capillary electrophoresis , locked nucleic acid-mediated polymerase chain reaction clamping , and high-resolution melting analysis . Although these methods possess a high specificity to assess NPM1 mutational status at diagnosis, they always require direct sequencing for NPM1m characterization, a more expensive and time-consuming method. We therefore investigated a new strategy where (i) mutational status, (ii) distinction between NPM1 mutation types, and (iii) quantitative value of the identified mutation at diagnosis would be rapidly obtained.
2. Materials and Methods
A series of 337 AML patients’ samples were referred to our laboratory for the initial diagnosis of AML from March 2007 to July 2011.
2.2. DNA and RNA Extraction
Mononuclear cells from bone marrow or blood samples were separated by Ficoll-Hypaque density gradient centrifugation (Histopaque Ficoll-1077, Sigma-Aldrich, Saint Louis, MI, USA) and stored as cellular suspensions containing 107 cells.
We extracted genomic DNA from aliquots of 107 mononuclear cells using the QIAamp DNA Mini Kit and the QIAcube instrument (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions, and aliquots containing DNA at 5 ng/μL were prepared.
RNA was extracted using the NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany), aliquots containing 1 μg RNA were prepared, and reverse transcription was performed as previously described .
Figure 1 presents an overview of the 2-step strategy we suggest to detect (first step) and identify (second step) the presence of NPM1m.
2.3. Screening by High-Resolution Melting
First, detection of NPM1m was carried out on genomic DNA by PCR and high-resolution melting (HRM) analysis. PCR reactions were performed in a 20 μL final volume containing 5 μL of genomic DNA and 300 nM of each primer (Eurogentec, Seraing, Belgium) (Table 1)  with 10 μL of LightCycler 480 Probe Master 2X (Roche Diagnostics, Mannheim, Germany), containing 3.2 mM MgCl2 and with 1 μL of ResoLight Dye 20X (Roche Diagnostics) as a nucleotide binding dye. Amplification (defining a 232 bp amplicon) was achieved by 45 cycles of 95°C for 10 secs, 56°C for 15 secs, and 72°C for 15 secs followed by a gene scanning analysis according to the manufacturers instructions by using the LightCycler 480 Real-Time PCR System instrument (Roche Diagnostics).
When HRM analysis revealed the presence of NPM1m, we proceeded to the second step (Figure 1). Identification and quantification of the different mutation types by allele-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) were performed by using 5 distinct RQ-PCR tubes containing a common forward primer, one of five different reverse primers (Eurogentec) designed to specifically target types A, B, C, D, and P mutations [11, 12], and a common probe (Life Technologies Corporation Applied Biosystems, Carlsbad, CA, USA) (Table 1). Each RQ-PCR mixture reaction contained 5 μL cDNA, 300 nM of each primer, 200 nM probe, and 10 μL of LightCycler 480 Probe Master 2X in a total volume of 20 μL. Preheating of the mixture at 95°C for 5 minutes was followed by 45 cycles of a 3-step cycle procedure (10 seconds at 95°C, 40 seconds at 62°C, and 1 second at 72°C). RQ-PCR of the endogenous reference gene ABL was accomplished as previously described [19, 20]. All quantitative PCRs were performed using Ipsogen plasmids (Ipsogen Cancer profiler, New Haven, CT, USA), and the assays were found to be linear over at least 5 orders of magnitude (slope: −3.350, −3.480, −3.349, −3.373, −3.305; intercept: 40.27, 40.53, 39.83, 39.66, 39.93 for mutations A, B, C, D, and P, resp.).
2.5. Mutational Analysis
Analysis was performed by a comparative cycle threshold (CT) method of relative quantification giving the amount of target, normalized to the ABL gene as follows: ΔCT = CT(NPM1m) − CT(ABL). The mutation type of each sample was identified using Table 2, which indicates the ΔCT profile obtained with each RQ-PCR primer depending on the mutation type.
This table had been previously built using a few patients (1–3 depending on mutation types) carrying known NPM1m. The ΔCT values were calculated from each known mutated sample (Table 2). Considering that the smallest CT value (as the ΔCT values) corresponds to the most specific primer, each mutation must be defined by the set of the different primers’ ΔCT values obtained:(i)mutations A, B, C, and P are clearly identified because the lowest ΔCT values are obtained with primer A, B, C, or P, respectively, as compared to those obtained with the other specific primers; (ii)in case of mutation D, both primers A and D have low ΔCT value. These two mutations can be discriminated since the ΔCT values of primers B, C, and P are far higher in case of type A than type D.
2.6. Sequencing Analysis of NPM1 Exon 12
To validate our method, we performed direct sequencing on a proportion of positive and negative cases with primer NPM1-AS. PCR-amplified fragments from 20 HRM-negative samples and 38 HRM-positive samples (cases with mutation detected by HRM analysis and identified by ASO-RQ-PCR using their ΔCT profile) were sequenced to confirm the results obtained with our strategy.
3. Results and Discussion
Among the 337 samples of AML diagnosis, the HRM screening revealed the presence of NPM1 mutation in 88 of them (26.1%). Typical results of HRM analysis are shown in Figure 2(a), allowing distinction between mutated and nonmutated samples. To confirm the absence of mutations and make sure that the new assay does not give false negative results, we investigated by direct sequencing 20 cases that were considered as NPM1m negative with the HRM analysis. All the cases proved to be wild-type sequences, which allowed us to consider our strategy as highly specific.
Among the 88 HRM-positive samples, the ASO-RQ-PCR and the use of Table 2 allowed us to identify the mutation type in 86 samples: 69 carried type A, 10 type B, 1 type C, 5 type D, and 1 type P. The different mutation types obtained using the ΔCT method were confirmed by direct sequencing in 36 samples (30 with mutation type A, 2 type B, 1 type C, 2 type D, and 1 type P), and none of them revealed any other mutation other than the one we identified with our ΔCT method. Thus, the results were fully correlated in 100% of the 36 sequenced samples.
Two samples identified by the HRM screening step showed ΔCT values which did not correspond to any of these mutation profiles showing the following values:(i)ΔCT = 0 with primer A and ΔCT = 16 with primers B, C, D, and P for the first sample;(ii)ΔCT = 15 with primer D and ΔCT = 16 with primers A, B, D, and P for the second one.
We then performed direct sequencing that revealed rare type Q (first sample) and M (second sample) NPM1 mutations.
The determination of the NPM1 mutation status in patients with AML is a new urgent requirement for patients enrolled in clinical trials, in order to stratify patients. Although the presence of mutation is currently associated with better outcome, irrespective of the type, its characterization at diagnosis is absolutely necessary for the monitoring of residual disease (MRD) during followup to assess the effectiveness of treatment and may help to identify patients likely to relapse prior to any haematological relapse. For each NPM1m patient, the MRD was performed from RNA with a high-sensitivity RQ-PCR method using NPM1m specific primers as described above (79 follow-up samples ranging from 0.0014% to 2800%; Figure 2(b) provides an example) and demonstrates that the assays are also suitable for the MRD.
Although Sanger sequencing represents so far the reference method to identify the mutation types for the first time at diagnosis, this expensive and labor-intensive technique does not represent the ideal way to routinely screen large numbers of patients. Using our strategy, mutation types can be identified since the global CT profiles are unique and surely define exclusively one type of mutation, without requiring sequencing. Besides, this method can be reproduced by each laboratory since it is based on the comparison of ΔCT and not only on raw CT values which could fluctuate between laboratories.
Recently, Barakat et al.  described a unique Q-PCR strategy to detect 6 of the most common NPM1m. This method presents the advantage to perform only one PCR reaction in a single tube. Nevertheless, it does not allow the identification of the mutation type which must be determined with an additional sequencing step to ensure the MRD. In addition, their assay was designed to screen only the most common NPM1 mutations and can fail to detect other rare types. Furthermore, among our 88 samples, we detected two rare mutation types (2.3%) that could have been missed or incorrectly identified with a one-tube Q-PCR strategy. Although other mutations are rare, they must not be missed given the importance of NPM1m for the molecular followup and therapeutic approaches in clinical trials. We could also avoid the HRM screen step, since samples without NPM1m were not amplified by the use of the different specific primers (101 negative remission samples tested as negative control) but, even if the M and Q mutations were amplified by our ASO-RQ-PCR approach, the first screening HRM step avoids missing truly rare but real NPM1 mutations. We then recommend the use of this method in routine screenings.
These results allow us to consider that our strategy is highly specific, and demonstrate in a large group of patients a reliable alternative to NPM1 sequencing in order to identify the most common NPM1m. This method provides a useful and inexpensive tool, easy to use in routine practice, and thus could be included in the genetic diagnosis workup of AML disease.
Conflict of Interests
The authors have no conflict of interests to declare regarding this paper.
The authors are grateful to “Pense à moelle,” “100% la vie” associations, and the “Direction de l’Hospitalisation et de l’Organisation des Soins” of the hospices civils de Lyon.
- B. Falini, C. Mecucci, E. Tiacci et al., “Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype,” New England Journal of Medicine, vol. 352, no. 3, pp. 254–266, 2005.
- D. A. Arber, R. D. Brunning, M. M. Le Beau, et al., “Acute myeloid leukemia with recurrent genetic abnormalities,” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, S. H. Swerdlow, E. Campo, N. L. Harris, et al., Eds., pp. 110–123, International Agency for Research on Cancer (IARC), 4th edition, 2008.
- B. Falini, M. P. Martelli, N. Bolli et al., “Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?” Blood, vol. 117, no. 4, pp. 1109–1120, 2011.
- G. S. Vassiliou, J. L. Cooper, R. Rad et al., “Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice,” Nature Genetics, vol. 43, no. 5, pp. 470–476, 2011.
- S. Schnittger, W. Kern, C. Tschulik et al., “Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML,” Blood, vol. 114, no. 11, pp. 2220–2231, 2009.
- T. Kristensen, M. B. Møller, L. Friis, O. J. Bergmann, and B. Preiss, “NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression,” European Journal of Haematology, vol. 87, no. 5, pp. 400–408, 2011.
- B. Falini, I. Gionfriddo, F. Cecchetti, S. Ballanti, V. Pettirossi, and M. P. Martelli, “Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?” Blood Reviews, vol. 25, no. 6, pp. 247–254, 2011.
- R. Rau and P. Brown, “Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity,” Hematological Oncology, vol. 27, no. 4, pp. 171–181, 2009.
- B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci, “Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features,” Blood, vol. 109, no. 3, pp. 874–885, 2007.
- T. Ottone, E. Ammatuna, S. Lavorgna et al., “An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia,” Journal of Molecular Diagnostics, vol. 10, no. 3, pp. 212–216, 2008.
- P. Gorello, G. Cazzaniga, F. Alberti et al., “Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations,” Leukemia, vol. 20, no. 6, pp. 1103–1108, 2006.
- S. Schnittger, C. Schoch, W. Kern et al., “Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype,” Blood, vol. 106, no. 12, pp. 3733–3739, 2005.
- D. Dvorakova, Z. Racil, I. Jeziskova et al., “Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations,” American Journal of Hematology, vol. 85, no. 12, pp. 926–929, 2010.
- E. Ammatuna, N. I. Noguera, D. Zangrilli et al., “Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC,” Clinical Chemistry, vol. 51, no. 11, pp. 2165–2167, 2005.
- N. I. Noguera, E. Ammatuna, D. Zangrilli et al., “Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia,” Leukemia, vol. 19, no. 8, pp. 1479–1482, 2005.
- C. Thiede, E. Creutzig, T. Illmer et al., “Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping,” Leukemia, vol. 20, no. 10, pp. 1897–1899, 2006.
- A. Y. Tan, D. A. Westerman, D. A. Carney, J. F. Seymour, S. Juneja, and A. Dobrovic, “Detection of NPM1 exon 12 mutations and FLT3—internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia,” Journal of Hematology & Oncology, vol. 1, p. 10, 2008.
- N. Boissel, A. Renneville, V. Biggio et al., “Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype,” Blood, vol. 106, no. 10, pp. 3618–3620, 2005.
- J. Gabert, E. Beillard, V. H. J. van der Velden et al., “Standardization and quality control studies of “real time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer Program,” Leukemia, vol. 17, no. 12, pp. 2318–2357, 2003.
- E. Beillard, N. Pallisgaard, V. H. J. van der Velden et al., “Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using “real-time” quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program,” Leukemia, vol. 17, no. 12, pp. 2474–2486, 2003.
- F. H. Barakat, R. Luthra, C. C. Yin et al., “Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study,” Archives of Pathology and Laboratory Medicine, vol. 135, no. 8, pp. 994–1000, 2011.